Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers

Pani, Arianna; Romandini, Alessandra; Schianchi, Alice; Senatore, Michele; Gagliardi, Oscar Matteo; Gazzaniga, Gianluca; S, Agliardi; Conti, Tommaso; Schenardi, Paolo; Maggi, Matteo; D’Onghia, Stefano; Panetta, Valentina; Renica, Silvia; Molteni, Silvia Nerini; Vismara, Chiara; Campisi, Daniela; Bertuzzi, Michaela; Giroldi, Simona; Zoppini, Laura; Moreno, Mauro; Merli, Marco; Bosio, Marco; Puoti, Massimo; Scaglione, Francesco

doi:10.3389/fimmu.2022.872667

Cited by 8 publications

(4 citation statements)

References 20 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After waning of S-antibody levels, further booster doses increase S-antibody levels again. We observed a marked increase in GMC shortly following the first booster compared to the primary series and a further increase after the second booster dose in line with previous findings (5,11,(19)(20)(21)(22). However, the increase in GMC shortly following the second booster compared to the first booster was much smaller.…”

Section: Discussionsupporting

confidence: 91%

COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study

Hoeve,

Huiberts,

de Gier

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Information on the magnitude and duration of antibody levels after COVID-19 vaccination in different groups may be useful for prioritizing of additional vaccinations. Methods Serum samples were collected every six months in a prospective cohort study among adults in the Netherlands. Geometric mean concentrations (GMCs) of antibodies against the receptor binding domain of the SARS-CoV-2 spike protein were calculated after the primary series, first, and second booster vaccinations. Effects of age (18-59 vs 60-85 years) and medical risk conditions on GMC 2-6 weeks and 21-25 weeks after each vaccination, and on waning during 3-25 weeks after each vaccination, were estimated by linear regression. Results We included 20,816, 16,820 and 5,879 samples collected after primary, first and second booster vaccination, respectively. GMCs at 2-6 and 21-25 weeks after primary series were lower in participants with older age or medical risk conditions. After the first booster, older age was associated with lower GMC at 2-6 weeks, higher GMC at 21-25 weeks, and slower waning. GMCs or waning after the first and second boosters (only 60-85) were not associated with medical risk conditions. Conclusions Since antibody differences by age and medical risk groups have become small with increasing number of doses, other factors such as disease severity rather than antibody levels are useful for prioritization of additional vaccinations.

show abstract

Section: Discussionsupporting

confidence: 91%

COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study

Hoeve,

Huiberts,

de Gier

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…All patients who had their booster vaccination during ofatumumab treatment showed an increase in neutralizing antibodies comparable to the cohorts vaccinated prior to ofatumumab or under other DMTs. However, while the relative increase was higher in patients with lower levels before the booster, higher pre-booster antibody levels seem to be associated with a higher absolute antibody level after the booster [ 23 ]. Antibody levels prior to the booster, in turn, are likely to depend on prior treatment.…”

Section: Discussionmentioning

confidence: 99%

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis

et al. 2023

View full text Add to dashboard Cite

Background: Few data exist on how ofatumumab treatment impacts SARS-CoV-2 booster vaccination response. Methods: KYRIOS is an ongoing prospective open-label multicenter study on the response to initial and booster SARS-CoV-2 mRNA vaccination before or during ofatumumab treatment in relapsing MS patients. The results on the initial vaccination cohort have been published previously. Here, we describe 23 patients who received their initial vaccination outside of the study but booster vaccination during the study. Additionally, we report the booster results of two patients in the initial vaccination cohort. The primary endpoint was SARS-CoV-2-specific T-cell response at month 1. Furthermore, serum total and neutralizing antibodies were measured. Results: The primary endpoint was reached by 87.5% of patients with booster before (booster cohort 1, N = 8) and 46.7% of patients with booster during ofatumumab treatment (booster cohort 2, N = 15). Seroconversion rates for neutralizing antibodies increased from 87.5% at baseline to 100.0% at month 1 in booster cohort 1 and from 71.4% to 93.3% in booster cohort 2. Of note, 3 of 4 initially seronegative patients in booster cohort 2 and one seronegative patient in the initial vaccination cohort seroconverted after the booster during ofatumumab treatment. Conclusions: Booster vaccinations increase neutralizing antibody titers in ofatumumab-treated patients. A booster is recommended in ofatumumab-treated patients.

show abstract

“…However, Yavuz et al (7) found no correlations between age or sex and postvaccination antibody titers after the third BNT162b2 vaccination. Pani et al (10) showed that mean increase in antibody titers is 42 times (CI 95% 40-45) for female subjects and 47 times (CI 95% 44-52) for males (p = 0.021). They reported a higher antibody titer increase rate in men than that in women after the third vaccination.…”

Section: Discussionmentioning

confidence: 99%

Febrile Reactions Associated with High IgG Antibody Titers after the Second and Third BNT162b2 Vaccinations in Japan

et al. 2023

View full text Add to dashboard Cite

Adverse events are potentially associated with an IgG response after the BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2. In this study, we investigated the side effects of BNT162b2 vaccination using a health questionnaire and examined its relationship with IgG antibody titers. Serum samples were collected from participants 3 months after the second vaccination, just before the third vaccination, and 1 and 3 months after the third vaccination. A total of 505 participants who received three doses of vaccination were eligible for analysis. The results showed that postvaccination body temperature correlated with anti-spike-receptor-binding domain (anti-S-RBD) antibody titers analyzed 3 months after the second (r = 0.30, p < 0.001) and third (r = 0.14, p < 0.001) vaccinations. Multivariate linear regression analysis revealed that age and severe swelling were negatively associated with log-transformed anti-S-RBD antibody levels, whereas sex (female), body temperature, and heat sensation were positively associated after the second vaccination. After the third vaccination, body temperature, and fatigue were positively associated with log-transformed anti-S-RBD antibody levels, and sex (female) was negatively associated. These results indicate that post-vaccination fever may be a marker of increased antibody titer.

show abstract

Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers

Cited by 8 publications

References 20 publications

COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study

COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis

Febrile Reactions Associated with High IgG Antibody Titers after the Second and Third BNT162b2 Vaccinations in Japan

Contact Info

Product

Resources

About